The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.
A user shared their 5-month progress using Finasteride (1mg daily) and 3 months on Oral Minoxidil (5mg daily) for hair regrowth, reporting significant improvement and no side effects. They experienced initial shedding with Minoxidil but saw substantial regrowth, encouraging others to try these treatments.
The user experienced significant hair regrowth using a combination of oral minoxidil (5mg) and dutasteride (0.5mg) along with monthly mesotherapy injections. Despite the progress, the user plans to proceed with a hair transplant to address a receding hairline that hasn't fully responded to the treatment.
The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.
A user shared progress pictures using 5mg oral minoxidil and 100mg spironolactone, noting increased body hair and faster nail growth. Another user humorously suggested a new sub for people with similar experiences.
The user has been using finasteride and minoxidil for five years but continues to experience hair thinning and density loss. They are considering switching to dutasteride for potentially better results.
The conversation is about using dutasteride 0.5mg, minoxidil 5%, and RU58841 for hair loss treatment. Users discuss dosage, potential side effects, and experiences with these treatments.
The user mixed RU58841 with Minoxidil for hair loss treatment and experienced reduced hair fall and thicker hair but stopped due to chest pain and muscle twitching. They plan to use a new routine without RU58841 or Finasteride due to side effects, including various topical treatments and peptides.
A user shared their 3-month hair regrowth progress using finasteride, minoxidil, Redensyl, and a derma roller, along with vitamin and biotin supplements. They have seen significant improvement and regained confidence, despite initially losing hair due to seborrheic dermatitis and male pattern baldness.
A 30-year-old male experienced significant hair regrowth after five months of using topical minoxidil (5% foam) and oral dutasteride (0.5 mg daily). The user reported no side effects and was grateful for the progress, despite the rapid gains slowing down.
Switching from finasteride to a generic dutasteride led to unexpectedly high DHT levels, prompting a switch to a reputed brand and consideration of softgel capsules for better absorption. The user plans to retest DHT levels and may return to finasteride if issues persist.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
The conversation is about the effectiveness of alfatradiol for hair loss and whether it can be used with or as a replacement for common treatments like minoxidil, finasteride, and RU58841. The user is seeking feedback on others' experiences with alfatradiol.
The conversation is about someone's three-year experience with irregular derma rolling, Minoxidil, and Redensyl for hair loss, hoping to thicken areas with fine hair.
PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
The user started using Pyrilutamide 5% for hair loss and has not experienced side effects after two days. They previously had side effects from Fluridil and topical Minoxidil 5%, and their hair continued thinning with topical Spironolactone.
The user experienced increased hair shedding after using RU58841 for two months, but found relief from scalp itchiness. Other users shared similar shedding experiences and discussed side effects like joint pain, while also mentioning the use of finasteride and minoxidil.
The user has been using 5% minoxidil foam for 5 months with noticeable results and is considering adding finasteride. Suggestions include adding finasteride, using hair fiber spray, and trying microneedling for better results.
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.
RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.